Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence.
Four sequential Aspergillus fumigatus isolates from a patient with chronic granulomatous disease (CGD) eventually failing azole-echinocandin combination therapy were investigated. The first two isolates (1 and 2) were susceptible to antifungal azoles, but increased itraconazole, voriconazole and posaconazole MICs were found for the last two isolates (3 and 4). Microsatellite typing showed that the 4 isolates were isogenic, suggesting that resistance had been acquired during azole treatment of the patient. An immunocompromised mouse model confirmed that the in vitro resistance corresponded with treatment failure. Mice challenged with the resistant isolate 4 failed to respond to posaconazole therapy, while those infected by susceptible isolate 2 responded. Posaconazole-anidulafungin combination therapy was effective in mice challenged with isolate 4. No mutations were found in the Cyp51A gene of the four isolates. However, expression experiments of the Cyp51A showed that the expression was increased in the resistant isolates, compared to the azole-susceptible isolates. The microscopic morphology of the four isolates was similar, but a clear alteration in radial growth and a significantly reduced growth rate of the resistant isolates on solid and in broth medium was observed compared to isolates 1 and 2 and to unrelated wild-type controls. In the mouse model the virulence of isolates 3 and 4 was reduced compared to the susceptible ones and to wild-type controls. For the first time, the acquisition of azole resistance despite azole-echinocandin combination therapy is described in a CGD patient and the resistance demonstrated to be directly associated with significant change of virulence.
Arendrup
Maiken Cavling
MC
Unit of Mycology and Parasitology, Statens Serum Institut, Copenhagen, Denmark. mad@ssi.dk
Mavridou
Eleftheria
E
Mortensen
Klaus Leth
KL
Snelders
Eveline
E
Frimodt-Møller
Niels
N
Khan
Humara
H
Melchers
Willem J G
WJ
Verweij
Paul E
PE
D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001232:Aspergillus fumigatus / Q000302:isolation & purification / Q000472:pathogenicity*; D001393:Azoles / Q000494:pharmacology / Q000627:therapeutic use*; D025141:Drug Resistance, Fungal; D004359:Drug Therapy, Combination; D006105:Granulomatous Disease, Chronic / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D051379:Mice; D014774:Virulence
D000935:Antifungal Agents; D001393:Azoles
Antimicrob Agents Chemother. 2004 Jul;48(7):2747-50
15215142
Med Mycol. 2005 May;43 Suppl 1:S207-38
16110814
Antimicrob Agents Chemother. 2008 Oct;52(10):3504-11
18644959
Clin Infect Dis. 2008 Feb 1;46(3):327-60
18177225
Antimicrob Agents Chemother. 1997 Oct;41(10):2229-37
9333053
Antimicrob Agents Chemother. 2003 Mar;47(3):1120-4
12604551
Antimicrob Agents Chemother. 2003 Feb;47(2):577-81
12543662
Clin Infect Dis. 2009 Apr 15;48(8):1111-3
19272019
Clin Microbiol Infect. 2009 Feb;15(2):180-7
19154486
J Antimicrob Chemother. 2005 Jan;55(1):31-7
15563516
Drug Resist Updat. 2009 Dec;12(6):141-7
19879181
Clin Microbiol Infect. 2008 Oct;14(10):982-4
18828858
Appl Environ Microbiol. 1995 Dec;61(12):4236-9
16535179
Emerg Infect Dis. 2009 Jul;15(7):1068-76
19624922
Antimicrob Agents Chemother. 2009 Mar;53(3):1185-93
19104024
Antimicrob Agents Chemother. 2005 Jun;49(6):2536-8
15917566
Lancet Infect Dis. 2009 Dec;9(12):789-95
19926038
N Engl J Med. 2007 Apr 5;356(14):1481-3
17409336
Appl Environ Microbiol. 2008 Jan;74(2):359-66
18024679
Antimicrob Agents Chemother. 2004 Nov;48(11):4405-13
15504870
Appl Environ Microbiol. 2000 Aug;66(8):3421-6
10919801
Antimicrob Agents Chemother. 2008 Jul;52(7):2468-72
18474574
Antimicrob Agents Chemother. 2003 May;47(5):1719-26
12709346
Appl Environ Microbiol. 2009 Jun;75(12):4053-7
19376899
Int J Antimicrob Agents. 2006 Nov;28(5):450-3
17034993
Stud Mycol. 2007;59:147-203
18490953
Appl Environ Microbiol. 2006 Apr;72(4):2581-5
16597960
J Clin Microbiol. 2003 Oct;41(10):4718-25
14532210
Antimicrob Agents Chemother. 1997 Jun;41(6):1364-8
9174200
J Clin Microbiol. 2001 Sep;39(9):3402-8
11526191
Antimicrob Agents Chemother. 2007 Jun;51(6):1897-904
17371828
J Antimicrob Chemother. 1997 Sep;40(3):401-14
9338494
Antimicrob Agents Chemother. 2010 Feb;54(2):860-5
19917751
PLoS Med. 2008 Nov 11;5(11):e219
18998768